Search by Drug Name or NDC
NDC 49281-0564-15 QUADRACEL 20; 5; 3; 20; 5; 15; 29; 7; 26 ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; [Lf]/.5mL; [Lf]/.5mL; [D'ag'U]/.5mL; [D'ag'U]/.5mL; [D'ag'U]/.5mL Details
QUADRACEL 20; 5; 3; 20; 5; 15; 29; 7; 26 ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; [Lf]/.5mL; [Lf]/.5mL; [D'ag'U]/.5mL; [D'ag'U]/.5mL; [D'ag'U]/.5mL
QUADRACEL is a INTRAMUSCULAR INJECTION, SUSPENSION in the VACCINE category. It is labeled and distributed by Sanofi Pasteur Inc.. The primary component is BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED); BORDETELLA PERTUSSIS FIMBRIAE 2/3 ANTIGEN; BORDETELLA PERTUSSIS PERTACTIN ANTIGEN; BORDETELLA PERTUSSIS TOXOID ANTIGEN (GLUTARALDEHYDE INACTIVATED); CLOSTRIDIUM TETANI TOXO.
MedlinePlus Drug Summary
Why get vaccinated? Polio vaccine can prevent polio. Polio (or poliomyelitis) is a disabling and lifethreatening disease caused by poliovirus, which can infect a person's spinal cord, leading to paralysis. Most people infected with polio have no symptoms, and many recover without complications. Some people will experience sore throat, fever, tiredness, nausea, headache, or stomach pain. A smaller group of people will develop more serious symptoms that affect the brain and spinal cord: Paresthesia (feeling of pins and needles in the legs), Meningitis (infection of the covering of the spinal cord and/or brain), or Paralysis (can't move parts of the body) or weakness in the arms, legs, or both. Paralysis is the most severe symptom associated with polio because it can lead to permanent disability and death. Improvements in limb paralysis can occur, but in some people new muscle pain and weakness may develop 15 to 40 years later. This is called "post-polio syndrome. Polio has been eliminated from the United States, but it still occurs in other parts of the world. The best way to protect yourself and keep the United States polio-free is to maintain high immunity (protection) in the population against polio through vaccination.
Related Packages: 49281-0564-15Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Polio Vaccine
Product Information
NDC | 49281-0564 |
---|---|
Product ID | 49281-564_36dac28e-f95b-4c27-a9f7-0d3a37e67bf3 |
Associated GPIs | 18990004351820 1899000435E620 |
GCN Sequence Number | 083062 |
GCN Sequence Number Description | diph,pertus(acel),tet,polio/PF VIAL 15-48-5-62 INTRAMUSC |
HIC3 | W7Z |
HIC3 Description | VACCINE/TOXOID PREPARATIONS,COMBINATIONS |
GCN | 51903 |
HICL Sequence Number | 035666 |
HICL Sequence Number Description | DIPHTHERIA, PERTUSSIS(ACELL),TETANUS,POLIO VACCINE/PF |
Brand/Generic | Brand |
Proprietary Name | QUADRACEL |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine |
Product Type | VACCINE |
Dosage Form | INJECTION, SUSPENSION |
Route | INTRAMUSCULAR |
Active Ingredient Strength | 20; 5; 3; 20; 5; 15; 29; 7; 26 |
Active Ingredient Units | ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL; [Lf]/.5mL; [Lf]/.5mL; [D'ag'U]/.5mL; [D'ag'U]/.5mL; [D'ag'U]/.5mL |
Substance Name | BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED); BORDETELLA PERTUSSIS FIMBRIAE 2/3 ANTIGEN; BORDETELLA PERTUSSIS PERTACTIN ANTIGEN; BORDETELLA PERTUSSIS TOXOID ANTIGEN (GLUTARALDEHYDE INACTIVATED); CLOSTRIDIUM TETANI TOXO |
Labeler Name | Sanofi Pasteur Inc. |
Pharmaceutical Class | Actively Acquired Immunity [PE], Actively Acquired Immunity [PE], Actively Acquired Immunity [PE], Actively Acquired Immunity [PE], Actively Acquired Immunity [PE], Actively Acquired Immunity [PE], Actively Acquired Immunity [PE], Actively Acquired Immuni |
DEA Schedule | n/a |
Marketing Category | BLA |
Application Number | BLA125525 |
Listing Certified Through | 2024-12-31 |
Package
NDC 49281-0564-15 (49281056415)
NDC Package Code | 49281-564-15 |
---|---|
Billing NDC | 49281056415 |
Package | 10 SYRINGE in 1 PACKAGE (49281-564-15) / .5 mL in 1 SYRINGE (49281-564-88) |
Marketing Start Date | 2015-03-24 |
NDC Exclude Flag | N |
Pricing Information | N/A |